How to Apply FAIR Principles to Clinical Trial Data Management for Better Transparency

Introduction: Why FAIR Principles Matter in Modern Trials

As clinical research increasingly adopts digital tools and open science policies, there is growing pressure to ensure that trial data is not only available but usable. This is where the FAIR principles—Findable, Accessible, Interoperable, and Reusable—come into play. These principles, first formalized in 2016, provide a structured approach to maximize the value of clinical data for stakeholders, regulators, and the public, without compromising patient privacy or regulatory compliance.

Implementing FAIR practices in clinical trial management improves data lifecycle integrity, enhances collaboration, and strengthens transparency—especially in the context of global trial registries and real-world evidence initiatives.

What Are the FAIR Principles?

FAIR data principles aim to make data:

• Findable: Data should be discoverable through well-described metadata and persistent identifiers.
• Accessible: Data should be retrievable via open protocols, with clearly defined access conditions.
• Interoperable: Data should use standardized vocabularies and formats for seamless integration.
• Reusable: Data should be richly described and licensed for reuse under clear conditions.

In the context of GxP-compliant clinical trials, these principles must be embedded into data planning, trial master file (TMF) strategies, and submission workflows.

Findable: Enhancing Discoverability of Trial Data

Findability starts with metadata. For clinical trials, metadata includes protocol IDs, study titles, trial phases, sponsor names, locations, and registry IDs (e.g., NCT number from ClinicalTrials.gov). To ensure findability:

• Register every interventional trial in a recognized registry like ISRCTN or the EU Clinical Trials Register.
• Use persistent identifiers (PIDs) like DOIs for datasets and publications.
• Ensure all datasets are accompanied by a metadata file (XML or JSON) with detailed attributes.
• Adopt CTMS (Clinical Trial Management Systems) that support indexation by external repositories.

Example: A Phase III oncology trial includes its data files in a Vivli repository with a unique DOI and cross-linked protocol metadata—this improves discoverability by both humans and machines.

Accessible: Ensuring Controlled Yet Transparent Access

Accessibility does not imply total openness. In clinical research, data must be accessible under FAIR-compliant conditions:

• Use open protocols like HTTPS or SFTP for data transfer.
• Define access levels—public, restricted, or controlled—based on sensitivity.
• Provide authentication layers where appropriate (e.g., IRB-approved researchers for patient-level data).
• Archive datasets in platforms like Vivli, YODA, or sponsor-controlled repositories with proper access logs.

Best practice is to embed a “Data Use Statement” in the metadata or as a README file, describing who can access the data and under what terms.

Interoperable: Speaking a Common Language Across Systems

Interoperability in clinical trials ensures that datasets from different systems, sites, or countries can be integrated for analysis. This requires:

• Standard formats like CDISC SDTM/ADaM for submission data
• Controlled vocabularies (e.g., MedDRA, WHO Drug Dictionary)
• Machine-readable metadata using formats like RDF or JSON-LD
• Clinical data interchange using HL7 FHIR APIs

Example Table: SDTM Conversion

Reusable: Planning for Long-Term Scientific Value

Data becomes reusable when it is sufficiently documented, licensed, and structured for others to apply it to new research. To meet the “R” in FAIR:

• Assign open licenses such as CC-BY or CC0 where possible
• Include study protocols, SAPs (Statistical Analysis Plans), and CRFs (Case Report Forms) as companion documents
• Ensure metadata explains variable derivation and transformation rules
• Apply version control to datasets, especially during data cleaning

Clinical data with strong reusability facilitates post-market surveillance, meta-analyses, and pharmacovigilance studies.

FAIR vs Regulatory Submissions: Compatible or Conflicting?

Regulatory bodies like the FDA, EMA, and PMDA have strict formats for data submission (eCTD, SDTM, ADaM). These formats are not inherently FAIR but can be FAIR-aligned if proper documentation, persistent IDs, and metadata are added. For example:

• FDA Data Standards Catalog supports CDISC-compliant submission aligned with FAIR principles.
• EMA’s Clinical Data Publication (Policy 0070) expects anonymized patient-level data with traceable documentation.

Thus, sponsors can align their trial data submissions with FAIR while meeting regulatory expectations.

Toolkits and Platforms Supporting FAIR Implementation

• FAIRshake: An evaluation tool for FAIRness scoring
• DATS: Data Tag Suite for biomedical metadata structuring
• DataCite: For issuing persistent DOIs for datasets
• Data Stewardship Wizard: A planning tool to implement FAIR at trial design phase

These tools help QA teams and clinical data managers to audit their data against FAIR indicators pre-submission.

Case Study: FAIR Implementation in an EU-Funded Vaccine Trial

An EU Horizon 2020 project on COVID-19 vaccines mandated FAIR-aligned data sharing. The sponsor followed this workflow:

1. Registered the trial in EudraCT and assigned a DOI to datasets
2. Used CDISC SDTM for data standardization
3. Published de-identified patient data in a public repository with metadata in RDF format
4. Tagged variables using UMLS for semantic interoperability
5. Assigned CC-BY license to enable unrestricted reuse

This example illustrates how FAIR can be implemented in real-world regulated trials without breaching compliance boundaries.

Best Practices Checklist for FAIR Clinical Trial Data

Conclusion: From Compliance to Culture

FAIR principles are more than just a data formatting checklist—they represent a shift in how we think about data stewardship, transparency, and public trust in clinical research. For pharma and clinical trial teams, embedding FAIR into the data lifecycle results in higher-quality science, smoother regulatory interactions, and broader societal impact. With the right planning, tools, and stakeholder commitment, FAIR data management can become not only achievable but standard across the industry.

Complying with ICMJE Guidelines on Clinical Trial Data Sharing Statements

Introduction: The Growing Importance of Data Sharing in Clinical Trials

In an era emphasizing transparency and reproducibility, data sharing has become a key ethical and regulatory expectation in clinical research. As part of this global movement, the International Committee of Medical Journal Editors (ICMJE) introduced mandatory data sharing statements for clinical trial manuscripts submitted on or after July 1, 2018.

This requirement applies to all interventional clinical trials involving human participants. The purpose is to inform readers, participants, and regulators whether the authors intend to share individual participant data (IPD), under what conditions, and through which mechanisms. This article offers a comprehensive guide to crafting ICMJE-compliant data sharing statements.

ICMJE Data Sharing Policy Overview

The ICMJE’s 2017 data sharing policy outlines the need for a clearly articulated data sharing plan at the time of trial registration, and a detailed statement at the time of publication. While data sharing is not mandated, transparency about intent is required. Specifically, authors must disclose:

• Whether they will share IPD
• What specific data will be shared (e.g., de-identified participant data, statistical analysis plans)
• When the data will become available and for how long
• By what access criteria (open access, upon request, or controlled access)
• Through which repository or system the data will be accessed

These requirements apply to trial manuscripts submitted to ICMJE-member journals and others that follow their editorial standards.

When and Where to Include the Data Sharing Statement

Authors are expected to register their data sharing plan in the trial registry (e.g., ClinicalTrials.gov, EU Clinical Trials Register) prior to patient enrollment. At the time of publication, the final data sharing statement must be included in the manuscript, often at the end of the “Methods” section or under a standalone “Data Sharing” heading.

ICMJE member journals, including The BMJ, The Lancet, and NEJM, have incorporated this requirement into their editorial workflows and will reject manuscripts that lack compliant disclosures.

Examples of ICMJE-Compliant Data Sharing Statements

To help authors, ICMJE offers sample formats. Examples include:

• “De-identified individual participant data (IPD) will be made available, including data dictionaries, beginning 3 months after publication and ending 5 years following article publication. Data will be accessible through request to the corresponding author.”
• “No IPD will be shared. The trial data is proprietary and part of a product development program.”
• “Only statistical analysis plans and protocol will be available upon request for researchers with an approved proposal.”

The key is clarity, specificity, and consistency between trial registry and publication.

Ethical Considerations in Data Sharing

While transparency is the goal, patient privacy and consent are non-negotiable. Ethical concerns include:

• Informed consent: Participants should be informed about potential future data sharing during enrollment.
• Anonymization: All shared data must be de-identified to prevent re-identification risk, especially in rare disease populations.
• Use limitations: Secondary use should align with ethical approval and not harm participants.

For global trials, sponsors must also consider compliance with jurisdictional laws like GDPR, HIPAA, and country-specific data protection acts.

Repositories and Platforms for Data Sharing

Data sharing must be feasible and secure. Authors can use a variety of established repositories depending on their region and data type:

• ClinicalStudyDataRequest.com (multi-sponsor)
• Vivli (global data sharing platform)
• YODA Project (Yale)
• Dryad, Zenodo, or institutional repositories for supplementary data files

Most repositories require submission of data use agreements and review of proposed research plans before granting access.

Data Sharing Plans and Trial Registration

When registering trials, sponsors must complete the data sharing section in registries like ClinicalTrials.gov. Required fields typically include:

• Plan to share IPD (Yes/No/Undecided)
• Description of data to be shared
• Additional documents to be shared (e.g., protocols, SAPs)
• Timeframe and access method

Consistency between registration, informed consent, and final publication is essential to ensure transparency and avoid post-approval scrutiny.

Data Sharing and ICMJE Journal Acceptance

Many ICMJE-compliant journals now reject trial manuscripts lacking proper data sharing disclosures. To improve acceptance odds, trial authors should:

• Align registry and manuscript disclosures
• Provide repository access links, if data are already available
• Mention any embargo or proprietary restrictions upfront

Journals such as BMJ Open, Trials (BMC), and PLOS ONE provide guidance on IPD sharing formats and encourage proactive archiving at submission stage.

Managing Risk in Data Reuse and Interpretation

One concern raised by sponsors is the misuse or misinterpretation of shared data. Strategies to manage this include:

• Using controlled access repositories
• Requiring data use agreements and approved protocols
• Requesting co-authorship or collaboration when appropriate

However, ethical guidelines generally discourage placing unnecessary restrictions on legitimate scientific inquiry using shared data.

Conclusion: Transparency Through Data Sharing

The ICMJE data sharing requirement is a landmark step toward greater transparency in clinical research. While not all trials may share IPD, all must clearly communicate their intent and access policies. By aligning ethical, legal, and publication responsibilities, trial sponsors and authors can fulfill both regulatory mandates and the public trust.

Planning data sharing from the protocol stage, obtaining proper consent, and ensuring robust data governance are essential to making this transparency sustainable and impactful.